ATXN3 and colonic neoplasm: Intriguingly, ATXN3 acts as an endogenous deubiquitinase of Galectin-9, thereby targeting ATXN3 deletion resulting in the reduced Galectin-9 expression and apoptosis of colon cancer cells.